Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability (Q36544988)

14 August 2017

1 reference

title

Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability (English)

1 reference

14 August 2017

organ transplantation

1 reference

Maria Shipkova

1

1 reference

14 August 2017

Victor William Armstrong

series ordinal

2

1 reference

14 August 2017

Michael Oellerich

series ordinal

3

1 reference

14 August 2017

Eberhard Wieland

series ordinal

4

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

1 reference

14 August 2017

1

1 reference

14 August 2017

3

1 reference

14 August 2017

505-526

1 reference

Outcomes in kidney transplantation

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil in solid-organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Immunosuppression for long-term maintenance of renal allograft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The use of mycophenolate mofetil in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Tacrolimus vs. cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Show me the money--immunosuppression in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Comparison of outcomes after delayed graft function: sirolimus-based versus other calcineurin-inhibitor sparing induction immunosuppression regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The design and development of an immunosuppressive drug, mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The inhibition of nucleic acid synthesis by mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The use of mycophenolate mofetil in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid inhibits inosine 5'-monophosphate dehydrogenase and suppresses immunoglobulin and cytokine production of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Effect of mycophenolate mofetil regimen on peripheral blood lymphocyte subsets in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacodynamics of mycophenolate mofetil after heart transplantation: new mechanisms of action and correlations with histologic severity of graft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Reduction of ICAM-1 and LFA-1-positive leukocytes in the perivascular space of arteries under mycophenolate mofetil therapy reduces rat heart transplant vasculopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The impact of immunosuppression on endothelial function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil prevents transplant arteriosclerosis by direct inhibition of vascular smooth muscle cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid antagonizes the activation of cultured human mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Cytoskeletal Reorganization by Mycophenolic Acid Alters Mesangial Cell Migration and Contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil reduces production of interferon-dependent major histocompatibility complex induction during allograft rejection, probably by limiting clonal expansion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Clinical pharmacokinetics of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate pharmacokinetics in early period following lung or heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic Acid Pharmacodynamics and Pharmacokinetics Provide a Basis for Rational Monitoring Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Reci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Acyl glucuronide drug metabolites: toxicological and analytical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Human UDP-glucuronosyltransferases show atypical metabolism of mycophenolic acid and inhibition by curcumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Influence of food on plasma concentration of mycophenolic acid in a heart transplant patient receiving concomitant tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Influence of ferrous sulfate on the solubility, partition coefficient, and stability of mycophenolic acid and the ester mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Impairment of mycophenolate mofetil absorption by calcium polycarbophil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid plasma concentrations: influence of comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Effect of cyclosporine withdrawal on mycophenolic acid pharmacokinetics in kidney transplant recipients with deteriorating renal function: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Cyclosporin A, but not tacrolimus, inhibits the biliary excretion of mycophenolic acid glucuronide possibly mediated by multidrug resistance-associated protein 2 in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mini-review: therapeutic drug monitoring in pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Unusual presentation of herpes virus infections in renal transplant recipients exposed to high mycophenolic acid plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

BK viral infection in an Australian pediatric renal transplant population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Post-transplantation lymphoproliferative disease in heart and heart-lung transplant recipients: 30-year experience at Stanford University

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Anemia in children after transplantation: etiology and the effect of immunosuppressive therapy on erythropoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Histologic Features of Mycophenolate Mofetil-Related Colitis: A Graft-Versus-Host Disease-Like Pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

A possible mechanism of gastrointestinal toxicity posed by mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

cDNA microarray analysis reveals new candidate genes possibly linked to side effects under mycophenolate mofetil therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pneumonitis associated with the use of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil: how to further improve using an already successful drug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pharmacodynamics of immunosuppressive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

African-American ethnicity is no longer a risk factor for early adverse outcomes in simultaneous kidney-pancreas transplantation with contemporary immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Long-term benefit of mycophenolate mofetil in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil versus azathioprine in patients surviving the initial cardiac transplant hospitalization: an analysis of the Joint UNOS/ISHLT Thoracic Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Long-term benefits of mycophenolate mofetil after heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Chronic cyclosporine-induced nephrotoxiciy in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Reduction of cyclosporine after introduction of mycophenolate mofetil improves chronic renal dysfunction in heart transplant recipients--the IMPROVED multi-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil in pediatric liver transplant patients with renal dysfunction: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil can be used as monotherapy late after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil: new applications for this immunosuppressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil in lupus glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Current and novel immunosuppressive therapy for autoimmune hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mycophenolate mofetil, Cellcept, a new immunosuppressive drug with great potential in internal medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

THE REJECTION OF RENAL HOMOGRAFTS

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

Mechanism of action of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.1.3.505

21 January 2018

Identifiers

DOI

10.1517/17425255.1.3.505

1 reference

14 August 2017

1 reference